FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969652358> ?p ?o ?g. }

• W2969652358 endingPage "e029808" @default.
• W2969652358 startingPage "e029808" @default.
• W2969652358 abstract "In women with gestational diabetes mellitus (GDM) requiring pharmacotherapy, insulin was the established first-line treatment. More recently, oral glucose lowering drugs (OGLDs) have gained popularity as a patient-friendly, less expensive and safe alternative. Monotherapy with metformin or glibenclamide (glyburide) is incorporated in several international guidelines. In women who do not reach sufficient glucose control with OGLD monotherapy, usually insulin is added, either with or without continuation of OGLDs. No reliable data from clinical trials, however, are available on the effectiveness of a treatment strategy using all three agents, metformin, glibenclamide and insulin, in a stepwise approach, compared with insulin-only therapy for improving pregnancy outcomes. In this trial, we aim to assess the clinical effectiveness, cost-effectiveness and patient experience of a stepwise combined OGLD treatment protocol, compared with conventional insulin-based therapy for GDM.The SUGAR-DIP trial is an open-label, multicentre randomised controlled non-inferiority trial. Participants are women with GDM who do not reach target glycaemic control with modification of diet, between 16 and 34 weeks of gestation. Participants will be randomised to either treatment with OGLDs, starting with metformin and supplemented as needed with glibenclamide, or randomised to treatment with insulin. In women who do not reach target glycaemic control with combined metformin and glibenclamide, glibenclamide will be substituted with insulin, while continuing metformin. The primary outcome will be the incidence of large-for-gestational-age infants (birth weight >90th percentile). Secondary outcome measures are maternal diabetes-related endpoints, obstetric complications, neonatal complications and cost-effectiveness analysis. Outcomes will be analysed according to the intention-to-treat principle.The study protocol was approved by the Ethics Committee of the Utrecht University Medical Centre. Approval by the boards of management for all participating hospitals will be obtained. Trial results will be submitted for publication in peer-reviewed journals.NTR6134; Pre-results." @default.
• W2969652358 created "2019-08-29" @default.
• W2969652358 creator A5000065760 @default.
• W2969652358 creator A5001814301 @default.
• W2969652358 creator A5008998287 @default.
• W2969652358 creator A5009649173 @default.
• W2969652358 creator A5010029482 @default.
• W2969652358 creator A5010988102 @default.
• W2969652358 creator A5011304299 @default.
• W2969652358 creator A5012943073 @default.
• W2969652358 creator A5013553895 @default.
• W2969652358 creator A5014578779 @default.
• W2969652358 creator A5014913703 @default.
• W2969652358 creator A5014981482 @default.
• W2969652358 creator A5015108573 @default.
• W2969652358 creator A5016039203 @default.
• W2969652358 creator A5017325442 @default.
• W2969652358 creator A5018111738 @default.
• W2969652358 creator A5018168326 @default.
• W2969652358 creator A5019498394 @default.
• W2969652358 creator A5024544592 @default.
• W2969652358 creator A5024619720 @default.
• W2969652358 creator A5025271326 @default.
• W2969652358 creator A5027649851 @default.
• W2969652358 creator A5029593427 @default.
• W2969652358 creator A5030464735 @default.
• W2969652358 creator A5031171375 @default.
• W2969652358 creator A5031266829 @default.
• W2969652358 creator A5031635786 @default.
• W2969652358 creator A5032824722 @default.
• W2969652358 creator A5034821116 @default.
• W2969652358 creator A5035147756 @default.
• W2969652358 creator A5035588554 @default.
• W2969652358 creator A5035723638 @default.
• W2969652358 creator A5035729614 @default.
• W2969652358 creator A5035794028 @default.
• W2969652358 creator A5038074463 @default.
• W2969652358 creator A5038662049 @default.
• W2969652358 creator A5039717738 @default.
• W2969652358 creator A5040617578 @default.
• W2969652358 creator A5042129418 @default.
• W2969652358 creator A5042312984 @default.
• W2969652358 creator A5042325549 @default.
• W2969652358 creator A5043228883 @default.
• W2969652358 creator A5047454112 @default.
• W2969652358 creator A5049539801 @default.
• W2969652358 creator A5049984033 @default.
• W2969652358 creator A5051265762 @default.
• W2969652358 creator A5052357202 @default.
• W2969652358 creator A5055836445 @default.
• W2969652358 creator A5057908866 @default.
• W2969652358 creator A5061948731 @default.
• W2969652358 creator A5063809316 @default.
• W2969652358 creator A5063991266 @default.
• W2969652358 creator A5065175958 @default.
• W2969652358 creator A5065789836 @default.
• W2969652358 creator A5068641868 @default.
• W2969652358 creator A5071444837 @default.
• W2969652358 creator A5071890730 @default.
• W2969652358 creator A5073370084 @default.
• W2969652358 creator A5074570683 @default.
• W2969652358 creator A5082305614 @default.
• W2969652358 creator A5083161436 @default.
• W2969652358 creator A5087451076 @default.
• W2969652358 creator A5087926076 @default.
• W2969652358 creator A5089320621 @default.
• W2969652358 creator A5090795384 @default.
• W2969652358 creator A5091885878 @default.
• W2969652358 date "2019-08-01" @default.
• W2969652358 modified "2023-10-14" @default.
• W2969652358 title "SUGAR-DIP trial: oral medication strategy versus insulin for diabetes in pregnancy, study protocol for a multicentre, open-label, non-inferiority, randomised controlled trial" @default.
• W2969652358 cites W1489717880 @default.
• W2969652358 cites W1497368056 @default.
• W2969652358 cites W1592674309 @default.
• W2969652358 cites W1964150654 @default.
• W2969652358 cites W1964286089 @default.
• W2969652358 cites W1979270297 @default.
• W2969652358 cites W1985850004 @default.
• W2969652358 cites W1990166011 @default.
• W2969652358 cites W2000357287 @default.
• W2969652358 cites W2003621575 @default.
• W2969652358 cites W2009961905 @default.
• W2969652358 cites W2020723228 @default.
• W2969652358 cites W2041720523 @default.
• W2969652358 cites W2042559024 @default.
• W2969652358 cites W2072554726 @default.
• W2969652358 cites W2074307717 @default.
• W2969652358 cites W2096962718 @default.
• W2969652358 cites W2097906965 @default.
• W2969652358 cites W2099733101 @default.
• W2969652358 cites W2131998216 @default.
• W2969652358 cites W2149300071 @default.
• W2969652358 cites W2150106013 @default.
• W2969652358 cites W2155041305 @default.
• W2969652358 cites W2169476389 @default.
• W2969652358 cites W2170514854 @default.
• W2969652358 cites W2171176478 @default.
• W2969652358 cites W2255104527 @default.

• next